Table of Content

1 Report Overview
1.1 Hepatic Encephalopathy Drug Definition
1.2 Market by Type
1.2.1 Global Hepatic Encephalopathy Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 RBX-2660
1.2.3 KLS-13019
1.2.4 GR-3027
1.2.5 SYNB-1020
1.2.6 Others
1.3 Market Segment by Application
1.3.1 Global Hepatic Encephalopathy Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Hepatic Encephalopathy Drug Sales
2.1 Global Hepatic Encephalopathy Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Hepatic Encephalopathy Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Hepatic Encephalopathy Drug Revenue by Region
2.3.1 Global Hepatic Encephalopathy Drug Revenue by Region (2018-2023)
2.3.2 Global Hepatic Encephalopathy Drug Revenue by Region (2024-2034)
2.4 Global Hepatic Encephalopathy Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Hepatic Encephalopathy Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Hepatic Encephalopathy Drug Sales Quantity by Region
2.6.1 Global Hepatic Encephalopathy Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Hepatic Encephalopathy Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Hepatic Encephalopathy Drug Sales Quantity by Manufacturers
3.1.1 Global Hepatic Encephalopathy Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Hepatic Encephalopathy Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Hepatic Encephalopathy Drug Sales in 2024
3.2 Global Hepatic Encephalopathy Drug Revenue by Manufacturers
3.2.1 Global Hepatic Encephalopathy Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Hepatic Encephalopathy Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Hepatic Encephalopathy Drug Revenue in 2024
3.3 Global Hepatic Encephalopathy Drug Sales Price by Manufacturers
3.4 Global Key Players of Hepatic Encephalopathy Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Hepatic Encephalopathy Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Hepatic Encephalopathy Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Hepatic Encephalopathy Drug, Product Offered and Application
3.8 Global Key Manufacturers of Hepatic Encephalopathy Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Hepatic Encephalopathy Drug Sales Quantity by Type
4.1.1 Global Hepatic Encephalopathy Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Hepatic Encephalopathy Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Hepatic Encephalopathy Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Hepatic Encephalopathy Drug Revenue by Type
4.2.1 Global Hepatic Encephalopathy Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Hepatic Encephalopathy Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Hepatic Encephalopathy Drug Revenue Market Share by Type (2018-2034)
4.3 Global Hepatic Encephalopathy Drug Price by Type
4.3.1 Global Hepatic Encephalopathy Drug Price by Type (2018-2023)
4.3.2 Global Hepatic Encephalopathy Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Hepatic Encephalopathy Drug Sales Quantity by Application
5.1.1 Global Hepatic Encephalopathy Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Hepatic Encephalopathy Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Hepatic Encephalopathy Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Hepatic Encephalopathy Drug Revenue by Application
5.2.1 Global Hepatic Encephalopathy Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Hepatic Encephalopathy Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Hepatic Encephalopathy Drug Revenue Market Share by Application (2018-2034)
5.3 Global Hepatic Encephalopathy Drug Price by Application
5.3.1 Global Hepatic Encephalopathy Drug Price by Application (2018-2023)
5.3.2 Global Hepatic Encephalopathy Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Hepatic Encephalopathy Drug Sales by Company
6.1.1 North America Hepatic Encephalopathy Drug Revenue by Company (2018-2023)
6.1.2 North America Hepatic Encephalopathy Drug Sales Quantity by Company (2018-2023)
6.2 North America Hepatic Encephalopathy Drug Market Size by Type
6.2.1 North America Hepatic Encephalopathy Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Hepatic Encephalopathy Drug Revenue by Type (2018-2034)
6.3 North America Hepatic Encephalopathy Drug Market Size by Application
6.3.1 North America Hepatic Encephalopathy Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Hepatic Encephalopathy Drug Revenue by Application (2018-2034)
6.4 North America Hepatic Encephalopathy Drug Market Size by Country
6.4.1 North America Hepatic Encephalopathy Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Hepatic Encephalopathy Drug Revenue by Country (2018-2034)
6.4.3 North America Hepatic Encephalopathy Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Hepatic Encephalopathy Drug Sales by Company
7.1.1 Europe Hepatic Encephalopathy Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Hepatic Encephalopathy Drug Revenue by Company (2018-2023)
7.2 Europe Hepatic Encephalopathy Drug Market Size by Type
7.2.1 Europe Hepatic Encephalopathy Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Hepatic Encephalopathy Drug Revenue by Type (2018-2034)
7.3 Europe Hepatic Encephalopathy Drug Market Size by Application
7.3.1 Europe Hepatic Encephalopathy Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Hepatic Encephalopathy Drug Revenue by Application (2018-2034)
7.4 Europe Hepatic Encephalopathy Drug Market Size by Country
7.4.1 Europe Hepatic Encephalopathy Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Hepatic Encephalopathy Drug Revenue by Country (2018-2034)
7.4.3 Europe Hepatic Encephalopathy Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Hepatic Encephalopathy Drug Sales by Company
8.1.1 China Hepatic Encephalopathy Drug Sales Quantity by Company (2018-2023)
8.1.2 China Hepatic Encephalopathy Drug Revenue by Company (2018-2023)
8.2 China Hepatic Encephalopathy Drug Market Size by Type
8.2.1 China Hepatic Encephalopathy Drug Sales Quantity by Type (2018-2034)
8.2.2 China Hepatic Encephalopathy Drug Revenue by Type (2018-2034)
8.3 China Hepatic Encephalopathy Drug Market Size by Application
8.3.1 China Hepatic Encephalopathy Drug Sales Quantity by Application (2018-2034)
8.3.2 China Hepatic Encephalopathy Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Hepatic Encephalopathy Drug Sales by Company
9.1.1 APAC Hepatic Encephalopathy Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Hepatic Encephalopathy Drug Revenue by Company (2018-2023)
9.2 APAC Hepatic Encephalopathy Drug Market Size by Type
9.2.1 APAC Hepatic Encephalopathy Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Hepatic Encephalopathy Drug Revenue by Type (2018-2034)
9.3 APAC Hepatic Encephalopathy Drug Market Size by Application
9.3.1 APAC Hepatic Encephalopathy Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Hepatic Encephalopathy Drug Revenue by Application (2018-2034)
9.4 APAC Hepatic Encephalopathy Drug Market Size by Region
9.4.1 APAC Hepatic Encephalopathy Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Hepatic Encephalopathy Drug Revenue by Region (2018-2034)
9.4.3 APAC Hepatic Encephalopathy Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Hepatic Encephalopathy Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Hepatic Encephalopathy Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Hepatic Encephalopathy Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Hepatic Encephalopathy Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Hepatic Encephalopathy Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Hepatic Encephalopathy Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Hepatic Encephalopathy Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Hepatic Encephalopathy Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Alfa Wassermann S.p.A
11.1.1 Alfa Wassermann S.p.A Company Information
11.1.2 Alfa Wassermann S.p.A Overview
11.1.3 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Products and Services
11.1.5 Alfa Wassermann S.p.A Hepatic Encephalopathy Drug SWOT Analysis
11.1.6 Alfa Wassermann S.p.A Recent Developments
11.2 Cosmo Pharmaceuticals S.p.A
11.2.1 Cosmo Pharmaceuticals S.p.A Company Information
11.2.2 Cosmo Pharmaceuticals S.p.A Overview
11.2.3 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Products and Services
11.2.5 Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug SWOT Analysis
11.2.6 Cosmo Pharmaceuticals S.p.A Recent Developments
11.3 Horizon Pharma Plc
11.3.1 Horizon Pharma Plc Company Information
11.3.2 Horizon Pharma Plc Overview
11.3.3 Horizon Pharma Plc Hepatic Encephalopathy Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Horizon Pharma Plc Hepatic Encephalopathy Drug Products and Services
11.3.5 Horizon Pharma Plc Hepatic Encephalopathy Drug SWOT Analysis
11.3.6 Horizon Pharma Plc Recent Developments
11.4 KannaLife Sciences, Inc.
11.4.1 KannaLife Sciences, Inc. Company Information
11.4.2 KannaLife Sciences, Inc. Overview
11.4.3 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Products and Services
11.4.5 KannaLife Sciences, Inc. Hepatic Encephalopathy Drug SWOT Analysis
11.4.6 KannaLife Sciences, Inc. Recent Developments
11.5 Ocera Therapeutics, Inc.
11.5.1 Ocera Therapeutics, Inc. Company Information
11.5.2 Ocera Therapeutics, Inc. Overview
11.5.3 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Products and Services
11.5.5 Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug SWOT Analysis
11.5.6 Ocera Therapeutics, Inc. Recent Developments
11.6 Rebiotix Inc.
11.6.1 Rebiotix Inc. Company Information
11.6.2 Rebiotix Inc. Overview
11.6.3 Rebiotix Inc. Hepatic Encephalopathy Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Rebiotix Inc. Hepatic Encephalopathy Drug Products and Services
11.6.5 Rebiotix Inc. Hepatic Encephalopathy Drug SWOT Analysis
11.6.6 Rebiotix Inc. Recent Developments
11.7 Spherium Biomed S.L.
11.7.1 Spherium Biomed S.L. Company Information
11.7.2 Spherium Biomed S.L. Overview
11.7.3 Spherium Biomed S.L. Hepatic Encephalopathy Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Spherium Biomed S.L. Hepatic Encephalopathy Drug Products and Services
11.7.5 Spherium Biomed S.L. Hepatic Encephalopathy Drug SWOT Analysis
11.7.6 Spherium Biomed S.L. Recent Developments
11.8 Umecrine Cognition AB
11.8.1 Umecrine Cognition AB Company Information
11.8.2 Umecrine Cognition AB Overview
11.8.3 Umecrine Cognition AB Hepatic Encephalopathy Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Umecrine Cognition AB Hepatic Encephalopathy Drug Products and Services
11.8.5 Umecrine Cognition AB Hepatic Encephalopathy Drug SWOT Analysis
11.8.6 Umecrine Cognition AB Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Hepatic Encephalopathy Drug Value Chain Analysis
12.2 Hepatic Encephalopathy Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Hepatic Encephalopathy Drug Production Mode & Process
12.4 Hepatic Encephalopathy Drug Sales and Marketing
12.4.1 Hepatic Encephalopathy Drug Sales Channels
12.4.2 Hepatic Encephalopathy Drug Distributors
12.5 Hepatic Encephalopathy Drug Customers
13 Market Dynamics
13.1 Hepatic Encephalopathy Drug Industry Trends
13.2 Hepatic Encephalopathy Drug Market Drivers
13.3 Hepatic Encephalopathy Drug Market Challenges
13.4 Hepatic Encephalopathy Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Hepatic Encephalopathy Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of RBX-2660
Table 3. Major Manufacturers of KLS-13019
Table 4. Major Manufacturers of GR-3027
Table 5. Major Manufacturers of SYNB-1020
Table 6. Major Manufacturers of Others
Table 7. Global Hepatic Encephalopathy Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Hepatic Encephalopathy Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 9. Global Hepatic Encephalopathy Drug Revenue by Region (2018-2023) & (US$ Million)
Table 10. Global Hepatic Encephalopathy Drug Revenue Market Share by Region (2018-2023)
Table 11. Global Hepatic Encephalopathy Drug Revenue by Region (2024-2034) & (US$ Million)
Table 12. Global Hepatic Encephalopathy Drug Revenue Market Share by Region (2024-2034)
Table 13. Global Hepatic Encephalopathy Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Pcs)
Table 14. Global Hepatic Encephalopathy Drug Sales by Region (2018-2023) & (K Pcs)
Table 15. Global Hepatic Encephalopathy Drug Sales Market Share by Region (2018-2023)
Table 16. Global Hepatic Encephalopathy Drug Sales by Region (2024-2034) & (K Pcs)
Table 17. Global Hepatic Encephalopathy Drug Sales Market Share by Region (2024-2034)
Table 18. Global Hepatic Encephalopathy Drug Sales Quantity by Manufacturers (2018-2023) & (K Pcs)
Table 19. Global Hepatic Encephalopathy Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 20. Global Hepatic Encephalopathy Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 21. Global Hepatic Encephalopathy Drug Revenue Share by Manufacturers (2018-2023)
Table 22. Global Hepatic Encephalopathy Drug Price by Manufacturers 2018-2023 (USD/Pcs)
Table 23. Global Key Players of Hepatic Encephalopathy Drug, Industry Ranking, 2021 VS 2024
Table 24. Global Hepatic Encephalopathy Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Hepatic Encephalopathy Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hepatic Encephalopathy Drug as of 2024)
Table 26. Global Key Manufacturers of Hepatic Encephalopathy Drug, Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of Hepatic Encephalopathy Drug, Product Offered and Application
Table 28. Global Key Manufacturers of Hepatic Encephalopathy Drug, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Hepatic Encephalopathy Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 31. Global Hepatic Encephalopathy Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 32. Global Hepatic Encephalopathy Drug Sales Quantity Share by Type (2018-2023)
Table 33. Global Hepatic Encephalopathy Drug Sales Quantity Share by Type (2024-2034)
Table 34. Global Hepatic Encephalopathy Drug Revenue by Type (2018-2023) & (US$ Million)
Table 35. Global Hepatic Encephalopathy Drug Revenue by Type (2024-2034) & (US$ Million)
Table 36. Global Hepatic Encephalopathy Drug Revenue Share by Type (2018-2023)
Table 37. Global Hepatic Encephalopathy Drug Revenue Share by Type (2024-2034)
Table 38. Hepatic Encephalopathy Drug Price by Type (2018-2023) & (USD/Pcs)
Table 39. Global Hepatic Encephalopathy Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 40. Global Hepatic Encephalopathy Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 41. Global Hepatic Encephalopathy Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 42. Global Hepatic Encephalopathy Drug Sales Quantity Share by Application (2018-2023)
Table 43. Global Hepatic Encephalopathy Drug Sales Quantity Share by Application (2024-2034)
Table 44. Global Hepatic Encephalopathy Drug Revenue by Application (2018-2023) & (US$ Million)
Table 45. Global Hepatic Encephalopathy Drug Revenue by Application (2024-2034) & (US$ Million)
Table 46. Global Hepatic Encephalopathy Drug Revenue Share by Application (2018-2023)
Table 47. Global Hepatic Encephalopathy Drug Revenue Share by Application (2024-2034)
Table 48. Hepatic Encephalopathy Drug Price by Application (2018-2023) & (USD/Pcs)
Table 49. Global Hepatic Encephalopathy Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 50. North America Hepatic Encephalopathy Drug Revenue by Company (2018-2023) & (US$ Million)
Table 51. North America Hepatic Encephalopathy Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 52. North America Hepatic Encephalopathy Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 53. North America Hepatic Encephalopathy Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 54. North America Hepatic Encephalopathy Drug Revenue by Type (2018-2023) & (US$ Million)
Table 55. North America Hepatic Encephalopathy Drug Revenue by Type (2024-2034) & (US$ Million)
Table 56. North America Hepatic Encephalopathy Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 57. North America Hepatic Encephalopathy Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 58. North America Hepatic Encephalopathy Drug Revenue by Application (2018-2023) & (US$ Million)
Table 59. North America Hepatic Encephalopathy Drug Revenue by Application (2024-2034) & (US$ Million)
Table 60. North America Hepatic Encephalopathy Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 61. North America Hepatic Encephalopathy Drug Revenue by Country (2018-2023) & (US$ Million)
Table 62. North America Hepatic Encephalopathy Drug Revenue by Country (2024-2034) & (US$ Million)
Table 63. North America Hepatic Encephalopathy Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 64. North America Hepatic Encephalopathy Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 65. Europe Hepatic Encephalopathy Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 66. Europe Hepatic Encephalopathy Drug Revenue by Company (2018-2023) & (US$ Million)
Table 67. Europe Hepatic Encephalopathy Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 68. Europe Hepatic Encephalopathy Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 69. Europe Hepatic Encephalopathy Drug Revenue by Type (2018-2023) & (US$ Million)
Table 70. Europe Hepatic Encephalopathy Drug Revenue by Type (2024-2034) & (US$ Million)
Table 71. Europe Hepatic Encephalopathy Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 72. Europe Hepatic Encephalopathy Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 73. Europe Hepatic Encephalopathy Drug Revenue by Application (2018-2023) & (US$ Million)
Table 74. Europe Hepatic Encephalopathy Drug Revenue by Application (2024-2034) & (US$ Million)
Table 75. Europe Hepatic Encephalopathy Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 76. Europe Hepatic Encephalopathy Drug Revenue by Country (2018-2023) & (US$ Million)
Table 77. Europe Hepatic Encephalopathy Drug Revenue by Country (2024-2034) & (US$ Million)
Table 78. Europe Hepatic Encephalopathy Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 79. Europe Hepatic Encephalopathy Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 80. China Hepatic Encephalopathy Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 81. China Hepatic Encephalopathy Drug Revenue by Company (2018-2023) & (US$ Million)
Table 82. China Hepatic Encephalopathy Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 83. China Hepatic Encephalopathy Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 84. China Hepatic Encephalopathy Drug Revenue by Type (2018-2023) & (US$ Million)
Table 85. China Hepatic Encephalopathy Drug Revenue by Type (2024-2034) & (US$ Million)
Table 86. China Hepatic Encephalopathy Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 87. China Hepatic Encephalopathy Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 88. China Hepatic Encephalopathy Drug Revenue by Application (2018-2023) & (US$ Million)
Table 89. China Hepatic Encephalopathy Drug Revenue by Application (2024-2034) & (US$ Million)
Table 90. APAC Hepatic Encephalopathy Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 91. APAC Hepatic Encephalopathy Drug Revenue by Company (2018-2023) & (US$ Million)
Table 92. APAC Hepatic Encephalopathy Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 93. APAC Hepatic Encephalopathy Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 94. APAC Hepatic Encephalopathy Drug Revenue by Type (2018-2023) & (US$ Million)
Table 95. APAC Hepatic Encephalopathy Drug Revenue by Type (2024-2034) & (US$ Million)
Table 96. APAC Hepatic Encephalopathy Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 97. APAC Hepatic Encephalopathy Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 98. APAC Hepatic Encephalopathy Drug Revenue by Application (2018-2023) & (US$ Million)
Table 99. APAC Hepatic Encephalopathy Drug Revenue by Application (2024-2034) & (US$ Million)
Table 100. APAC Hepatic Encephalopathy Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 101. APAC Hepatic Encephalopathy Drug Revenue by Region (2018-2023) & (US$ Million)
Table 102. APAC Hepatic Encephalopathy Drug Revenue by Region (2024-2034) & (US$ Million)
Table 103. APAC Hepatic Encephalopathy Drug Sales Quantity by Region (2018-2023) & (K Pcs)
Table 104. APAC Hepatic Encephalopathy Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 105. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 106. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue by Company (2018-2023) & (US$ Million)
Table 107. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 108. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 109. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue by Type (2018-2023) & (US$ Million)
Table 110. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue by Type (2024-2034) & (US$ Million)
Table 111. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 112. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 113. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue by Application (2018-2023) & (US$ Million)
Table 114. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue by Application (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 116. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue by Country (2018-2023) & (US$ Million)
Table 117. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue by Country (2024-2034) & (US$ Million)
Table 118. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 119. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 120. Alfa Wassermann S.p.A Company Information
Table 121. Alfa Wassermann S.p.A Description and Overview
Table 122. Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 123. Alfa Wassermann S.p.A Hepatic Encephalopathy Drug Product and Services
Table 124. Alfa Wassermann S.p.A Hepatic Encephalopathy Drug SWOT Analysis
Table 125. Alfa Wassermann S.p.A Recent Developments
Table 126. Cosmo Pharmaceuticals S.p.A Company Information
Table 127. Cosmo Pharmaceuticals S.p.A Description and Overview
Table 128. Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 129. Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug Product and Services
Table 130. Cosmo Pharmaceuticals S.p.A Hepatic Encephalopathy Drug SWOT Analysis
Table 131. Cosmo Pharmaceuticals S.p.A Recent Developments
Table 132. Horizon Pharma Plc Company Information
Table 133. Horizon Pharma Plc Description and Overview
Table 134. Horizon Pharma Plc Hepatic Encephalopathy Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 135. Horizon Pharma Plc Hepatic Encephalopathy Drug Product and Services
Table 136. Horizon Pharma Plc Hepatic Encephalopathy Drug SWOT Analysis
Table 137. Horizon Pharma Plc Recent Developments
Table 138. KannaLife Sciences, Inc. Company Information
Table 139. KannaLife Sciences, Inc. Description and Overview
Table 140. KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 141. KannaLife Sciences, Inc. Hepatic Encephalopathy Drug Product and Services
Table 142. KannaLife Sciences, Inc. Hepatic Encephalopathy Drug SWOT Analysis
Table 143. KannaLife Sciences, Inc. Recent Developments
Table 144. Ocera Therapeutics, Inc. Company Information
Table 145. Ocera Therapeutics, Inc. Description and Overview
Table 146. Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 147. Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug Product and Services
Table 148. Ocera Therapeutics, Inc. Hepatic Encephalopathy Drug SWOT Analysis
Table 149. Ocera Therapeutics, Inc. Recent Developments
Table 150. Rebiotix Inc. Company Information
Table 151. Rebiotix Inc. Description and Overview
Table 152. Rebiotix Inc. Hepatic Encephalopathy Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 153. Rebiotix Inc. Hepatic Encephalopathy Drug Product and Services
Table 154. Rebiotix Inc. Hepatic Encephalopathy Drug SWOT Analysis
Table 155. Rebiotix Inc. Recent Developments
Table 156. Spherium Biomed S.L. Company Information
Table 157. Spherium Biomed S.L. Description and Overview
Table 158. Spherium Biomed S.L. Hepatic Encephalopathy Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 159. Spherium Biomed S.L. Hepatic Encephalopathy Drug Product and Services
Table 160. Spherium Biomed S.L. Hepatic Encephalopathy Drug SWOT Analysis
Table 161. Spherium Biomed S.L. Recent Developments
Table 162. Umecrine Cognition AB Company Information
Table 163. Umecrine Cognition AB Description and Overview
Table 164. Umecrine Cognition AB Hepatic Encephalopathy Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 165. Umecrine Cognition AB Hepatic Encephalopathy Drug Product and Services
Table 166. Umecrine Cognition AB Hepatic Encephalopathy Drug SWOT Analysis
Table 167. Umecrine Cognition AB Recent Developments
Table 168. Key Raw Materials Lists
Table 169. Raw Materials Key Suppliers Lists
Table 170. Hepatic Encephalopathy Drug Distributors List
Table 171. Hepatic Encephalopathy Drug Customers List
Table 172. Hepatic Encephalopathy Drug Market Trends
Table 173. Hepatic Encephalopathy Drug Market Drivers
Table 174. Hepatic Encephalopathy Drug Market Challenges
Table 175. Hepatic Encephalopathy Drug Market Restraints
Table 176. Research Programs/Design for This Report
Table 177. Key Data Information from Secondary Sources
Table 178. Key Data Information from Primary Sources
List of Figures
Figure 1. Hepatic Encephalopathy Drug Product Picture
Figure 2. Global Hepatic Encephalopathy Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Hepatic Encephalopathy Drug Market Share by Type in 2024 & 2034
Figure 4. RBX-2660 Product Picture
Figure 5. KLS-13019 Product Picture
Figure 6. GR-3027 Product Picture
Figure 7. SYNB-1020 Product Picture
Figure 8. Others Product Picture
Figure 9. Global Hepatic Encephalopathy Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 10. Global Hepatic Encephalopathy Drug Market Share by Application in 2024 & 2034
Figure 11. Clinic
Figure 12. Hospital
Figure 13. Others
Figure 14. Hepatic Encephalopathy Drug Report Years Considered
Figure 15. Global Hepatic Encephalopathy Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 16. Global Hepatic Encephalopathy Drug Revenue 2018-2034 (US$ Million)
Figure 17. Global Hepatic Encephalopathy Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 18. Global Hepatic Encephalopathy Drug Sales Quantity 2018-2034 (K Pcs)
Figure 19. Global Hepatic Encephalopathy Drug Sales Quantity Market Share by Region (2018-2023)
Figure 20. Global Hepatic Encephalopathy Drug Sales Quantity Market Share by Region (2024-2034)
Figure 21. North America Hepatic Encephalopathy Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 22. North America Hepatic Encephalopathy Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 23. Europe Hepatic Encephalopathy Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 24. Europe Hepatic Encephalopathy Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 25. China Hepatic Encephalopathy Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 26. China Hepatic Encephalopathy Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 27. APAC Hepatic Encephalopathy Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 28. APAC Hepatic Encephalopathy Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 29. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 30. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 31. The Top 10 and Top 5 Players Market Share by Hepatic Encephalopathy Drug Sales Quantity in 2024
Figure 32. The Top 10 and Top 5 Players Market Share by Hepatic Encephalopathy Drug Revenue in 2024
Figure 33. Hepatic Encephalopathy Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 34. Global Hepatic Encephalopathy Drug Sales Quantity Market Share by Type (2018-2034)
Figure 35. Global Hepatic Encephalopathy Drug Revenue Market Share by Type (2018-2034)
Figure 36. Global Hepatic Encephalopathy Drug Sales Quantity Market Share by Application (2018-2034)
Figure 37. Global Hepatic Encephalopathy Drug Revenue Market Share by Application (2018-2034)
Figure 38. North America Hepatic Encephalopathy Drug Revenue Market Share by Company in 2024
Figure 39. North America Hepatic Encephalopathy Drug Sales Quantity Market Share by Company in 2024
Figure 40. North America Hepatic Encephalopathy Drug Sales Quantity Market Share by Type (2018-2034)
Figure 41. North America Hepatic Encephalopathy Drug Revenue Market Share by Type (2018-2034)
Figure 42. North America Hepatic Encephalopathy Drug Sales Quantity Market Share by Application (2018-2034)
Figure 43. North America Hepatic Encephalopathy Drug Revenue Market Share by Application (2018-2034)
Figure 44. North America Hepatic Encephalopathy Drug Revenue Share by Country (2018-2034)
Figure 45. North America Hepatic Encephalopathy Drug Sales Quantity Share by Country (2018-2034)
Figure 46. U.S. Hepatic Encephalopathy Drug Revenue (2018-2034) & (US$ Million)
Figure 47. Canada Hepatic Encephalopathy Drug Revenue (2018-2034) & (US$ Million)
Figure 48. Europe Hepatic Encephalopathy Drug Sales Quantity Market Share by Company in 2024
Figure 49. Europe Hepatic Encephalopathy Drug Revenue Market Share by Company in 2024
Figure 50. Europe Hepatic Encephalopathy Drug Sales Quantity Market Share by Type (2018-2034)
Figure 51. Europe Hepatic Encephalopathy Drug Revenue Market Share by Type (2018-2034)
Figure 52. Europe Hepatic Encephalopathy Drug Sales Quantity Market Share by Application (2018-2034)
Figure 53. Europe Hepatic Encephalopathy Drug Revenue Market Share by Application (2018-2034)
Figure 54. Europe Hepatic Encephalopathy Drug Revenue Share by Country (2018-2034)
Figure 55. Europe Hepatic Encephalopathy Drug Sales Quantity Share by Country (2018-2034)
Figure 56. Germany Hepatic Encephalopathy Drug Revenue (2018-2034) & (US$ Million)
Figure 57. France Hepatic Encephalopathy Drug Revenue (2018-2034) & (US$ Million)
Figure 58. U.K. Hepatic Encephalopathy Drug Revenue (2018-2034) & (US$ Million)
Figure 59. Italy Hepatic Encephalopathy Drug Revenue (2018-2034) & (US$ Million)
Figure 60. Russia Hepatic Encephalopathy Drug Revenue (2018-2034) & (US$ Million)
Figure 61. China Hepatic Encephalopathy Drug Sales Quantity Market Share by Company in 2024
Figure 62. China Hepatic Encephalopathy Drug Revenue Market Share by Company in 2024
Figure 63. China Hepatic Encephalopathy Drug Sales Quantity Market Share by Type (2018-2034)
Figure 64. China Hepatic Encephalopathy Drug Revenue Market Share by Type (2018-2034)
Figure 65. China Hepatic Encephalopathy Drug Sales Quantity Market Share by Application (2018-2034)
Figure 66. China Hepatic Encephalopathy Drug Revenue Market Share by Application (2018-2034)
Figure 67. APAC Hepatic Encephalopathy Drug Sales Quantity Market Share by Company in 2024
Figure 68. APAC Hepatic Encephalopathy Drug Revenue Market Share by Company in 2024
Figure 69. APAC Hepatic Encephalopathy Drug Sales Quantity Market Share by Type (2018-2034)
Figure 70. APAC Hepatic Encephalopathy Drug Revenue Market Share by Type (2018-2034)
Figure 71. APAC Hepatic Encephalopathy Drug Sales Quantity Market Share by Application (2018-2034)
Figure 72. APAC Hepatic Encephalopathy Drug Revenue Market Share by Application (2018-2034)
Figure 73. APAC Hepatic Encephalopathy Drug Revenue Share by Region (2018-2034)
Figure 74. APAC Hepatic Encephalopathy Drug Sales Quantity Share by Region (2018-2034)
Figure 75. Japan Hepatic Encephalopathy Drug Revenue (2018-2034) & (US$ Million)
Figure 76. South Korea Hepatic Encephalopathy Drug Revenue (2018-2034) & (US$ Million)
Figure 77. China Taiwan Hepatic Encephalopathy Drug Revenue (2018-2034) & (US$ Million)
Figure 78. Southeast Asia Hepatic Encephalopathy Drug Revenue (2018-2034) & (US$ Million)
Figure 79. India Hepatic Encephalopathy Drug Revenue (2018-2034) & (US$ Million)
Figure 80. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Sales Quantity Market Share by Company in 2024
Figure 81. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue Market Share by Company in 2024
Figure 82. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Sales Quantity Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue Market Share by Type (2018-2034)
Figure 84. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Sales Quantity Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue Market Share by Application (2018-2034)
Figure 86. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Sales Quantity Share by Country (2018-2034)
Figure 87. Middle East, Africa and Latin America Hepatic Encephalopathy Drug Revenue Share by Country (2018-2034)
Figure 88. Brazil Hepatic Encephalopathy Drug Revenue (2018-2034) & (US$ Million)
Figure 89. Mexico Hepatic Encephalopathy Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Turkey Hepatic Encephalopathy Drug Revenue (2018-2034) & (US$ Million)
Figure 91. Israel Hepatic Encephalopathy Drug Revenue (2018-2034) & (US$ Million)
Figure 92. GCC Countries Hepatic Encephalopathy Drug Revenue (2018-2034) & (US$ Million)
Figure 93. Hepatic Encephalopathy Drug Value Chain
Figure 94. Hepatic Encephalopathy Drug Production Process
Figure 95. Channels of Distribution (Direct Vs Distribution)
Figure 96. Distributors Profiles
Figure 97. Bottom-up and Top-down Approaches for This Report
Figure 98. Data Triangulation
Figure 99. Key Executives Interviewed